Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This tool was developed to enhance reproducibility and sensitivity in measuring partial hair regrowth in alopecia areata patients, particularly those undergoing JAK inhibitor therapy, using scalp photographs.

In this study, ritlecitinib, an oral JAK3/TEC inhibitor, was evaluated for safety in patients aged 12 and older with alopecia areata across four clinical trials up to 36 months, showing a safety profile with reported adverse events and lab abnormalities summarized per dosing groups.

This study provides evidence supporting a regulatory relationship between the transcriptional regulator Hoxc13 and Krtap16 genes, which are crucial for proper hair growth in mice.

This study reported that patients with alopecia areata treated with ritlecitinib in a real-life setting had a higher rate of positive response on the Severity of Alopecia Tool score compared to those in the ALLEGRO trial.

This study found that activation of RORA significantly promotes the level of autophagy in rat hair follicle stem cells, suggesting a potential target for research on hair follicle development and treatments for conditions like alopecia.

This article is an abstract header with author credentials and reports no study findings.

This study found that different stabilizing mutations in Aux/IAA proteins affect root hair development in Arabidopsis by disrupting the auxin response and suggest a model where the relative abundance of these proteins determines root hair initiation.

This announcement provides updated information for members and participants of the 24th ISHRS World Congress of Hair Restoration Surgery, without reporting any new research findings.

This study reported that ritlecitinib was generally well tolerated over 72 months in patients aged 12 and older with alopecia areata, with adverse events like headache and nasopharyngitis observed, and safety outcomes consistent with previous studies.

This study examined the safety profile of ritlecitinib, a drug for alopecia areata, and found that it does not cause significant QTc prolongation or severe lymphopenia, with no unique safety risks expected in adolescents.

Ritlecitinib helps adolescents with severe alopecia areata regrow scalp hair and normalize body hair and nails.

Ritlecitinib significantly regrows scalp hair in people with alopecia areata.

In this Italian retrospective study, ritlecitinib 50 mg/day showed effectiveness and good tolerability for treating severe alopecia areata over 24 weeks, achieving significant hair regrowth particularly in adolescents, as well as improvements in eyebrows, eyelashes, nails, and quality of life, with mostly mild adverse effects.

This study found that ritlecitinib improved patient-reported outcomes related to hair growth in individuals with alopecia areata, with some experiencing clinically meaningful hair regrowth, although changes in emotional symptoms and activity limitations were minimal and similar across treatment groups.

This study identified a novel mechanism by which dsRNA-induced TLR3 activation and retinoic acid pathways contribute to new hair follicle formation after deep wounds in mice and suggested a similar potential in humans.

In this study, researchers developed an open-source browser-based tool to enhance the reproducibility and accuracy of SALT score calculations from scalp photos, aimed particularly at assessing partial regrowth in alopecia areata patients on JAK inhibitor therapy.

In this study, participants receiving a 50-mg maintenance dose of ritlecitinib reported greater improvements in emotional and activity limitations due to hair loss by Week 48 compared to those on a 10-mg dose.

This study found that ion-paired solutions significantly improved the skin penetration of risedronate in hairless mice compared to risedronate alone.

In this real-world study, 27% of alopecia areata patients treated with ritlecitinib achieved a target SALT score, a result consistent with clinical trial findings, highlighting the value of patient-reported outcomes in understanding treatment impact beyond traditional measures.

This study reports that a new mouse model with a CARD14 mutation successfully mimics key human PRP symptoms, and anti-IL-17A antibody significantly reduces these symptoms.

In this study, the authors reported that AtRXR3, a phosphorus-inducible DUF506 protein, modulates root hair growth under phosphorus stress by interacting with calmodulin and influencing calcium oscillations.

RCS-01 is safe and may help rejuvenate aging skin.

In this study, Ritlecitinib was reported as a newly approved treatment for alopecia areata that can be used in patients aged 12 and older; after 24 weeks, it resulted in 80% or more scalp hair coverage in treated patients compared to a placebo.

TEDAR is crucial for skin cell differentiation and barrier formation.

This article reviews the author's experience and favored techniques for using Radiesse in cosmetic treatments but reports no new clinical trial results.

This study established a stable cell line for CRF1 receptor screening, which can be used to develop functional cosmetics and modulators potentially affecting hair re-growth.

In this study, real-world data of 31 patients using ritlecitinib for severe alopecia areata showed that 51% achieved significant hair regrowth after one year, with no serious adverse events reported, emphasizing the importance of considering treatment duration for response.